Related Experiment Video

Updated: Jul 19, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Experimental use of GnRH antagonists as second-line hormonal therapy

Tomasz M Beer

    Reviews in Urology
    |September 21, 2006
    PubMed

    Insights

    Abarelix, a gonadotropin-releasing hormone antagonist, was tested in men with androgen-independent prostate cancer (AIPC). Orchiectomy patients showed improved outcomes, suggesting FSH may drive AIPC progression.

    Area of Science:

    • Oncology
    • Endocrinology
    • Urology

    Background:

    • Preclinical studies suggest follicle-stimulating hormone (FSH) signaling promotes androgen-independent prostate cancer (AIPC) progression.
    • Abarelix, a GnRH antagonist, effectively suppresses FSH with minimal impact on testosterone levels.
    • This study aimed to test the hypothesis that FSH supports AIPC progression.

    Purpose of the Study:

    • To evaluate the efficacy of abarelix in patients with early AIPC.
    • To determine if FSH suppression by abarelix impacts AIPC progression.
    • To compare abarelix's effects in patients previously treated with LHRH agonists versus orchiectomy.

    Main Methods:

    • Abarelix was administered to two groups of men with early AIPC.
    • Group 1: Patients previously treated with luteinizing hormone-releasing hormone (LHRH) agonist therapy.
    • Group 2: Patients who had undergone orchiectomy.

    Main Results:

    • No confirmed treatment response was observed in either group.
    • Patients treated with orchiectomy demonstrated a higher time to progression.
    • Orchiectomy patients also showed a greater fraction of patients progression-free and with PSA reductions >50%.

    Conclusions:

    • The study generated a hypothesis that circulating FSH may support AIPC progression.
    • Orchiectomy appears to yield better outcomes than LHRH agonist therapy in this context.
    • Further investigation, including a Phase I trial for abarelix dosage escalation, is warranted.

    More Related Videos

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies06:24

    Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

    Published on: January 10, 2025

    Related Concept Videos

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

    Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

    5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

    Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

    Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
    Cholinergic Antagonists: Therapeutic Uses01:26

    Cholinergic Antagonists: Therapeutic Uses

    Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
    Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
    Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

    Direct-Acting Cholinergic Agonists: Therapeutic Uses

    Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

    Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

    Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
    Phenothiazines, such as prochlorperazine...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...